{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:44:44Z","timestamp":1758282284276,"version":"3.44.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Venetoclax is effective in treating relapsed acute promyelocytic leukemia (APL), newly diagnosed pediatric APL, variant APL, and APL with central nervous system involvement. In newly diagnosed adult APL, venetoclax is rarely used. Herein, we present a case of newly diagnosed adult APL in a 35-year-old female with schizophrenia who received venetoclax as a cytoreduction therapy option. The patient was admitted with myocardial ischemia, the cardiac ultrasound indicating left ventricular ejection fractions (EF) of 44%, a 17-year history of schizophrenia, treated with ziprasidone, lorazepam, and clozapine. She developed differentiation syndrome (DS) shortly after receiving All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) and experienced heart arrest. In the occurrence of DS, this young female encountered numerous therapeutic conundrums, including cytoreduction of hydroxyurea being ineffective, the potential psychological worsening caused by dexamethasone use, and the cardiotoxicity of anthracyclines. We administered venetoclax 20 mg once daily as a cytoreduction therapy. The white blood cells (WBC) dropped from 72.16\u00d710<jats:sup>9<\/jats:sup>\/L to 5.19\u00d710<jats:sup>9<\/jats:sup>\/L in 4 days, and the proportion of promyelocytes in the peripheral blood smear decreased from 78% to 10%. Tumor lysis syndrome (TLS) did not develop since the patient received good supportive treatment. For newly diagnosed adult patients with APL who are unresponsive to traditional cytoreduction therapy, venetoclax can be an effective option.<\/jats:p>","DOI":"10.3389\/fonc.2025.1671529","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:14:02Z","timestamp":1758168842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Venetoclax as a cytoreduction therapy option for acute promyelocytic leukemia in newly diagnosed adult patients: a case report of a 35-year-old female with schizophrenia"],"prefix":"10.3389","volume":"15","author":[{"given":"Lingling","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuexin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1056\/NEJMicm2314162","article-title":"Acute promyelocytic leukemia","volume":"390","author":"Winkler","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279052","article-title":"Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all","volume":"107","author":"Schuh","year":"2022","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113451","article-title":"Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia","volume":"220","author":"Liang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284421","article-title":"Evolution in treatment of acute promyelocytic leukemia: a major victory","volume":"109","author":"Tallman","year":"2024","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12885-023-10612-z","article-title":"Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021","volume":"23","author":"Gill","year":"2023","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2391098","article-title":"Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide\/all-trans retinoic acid\/ascorbic acid the answer","volume":"17","author":"Gill","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic Malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024009","article-title":"How I treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/bjh.18061","article-title":"Venetoclax for arsenic-resistant acute promyelocytic leukaemia","volume":"197","author":"Wang","year":"2022","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19119","article-title":"Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience","volume":"203","author":"Qi","year":"2023","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23671","article-title":"Venetoclax overcomes resistance to all-trans retinoic acid in a variant acute promyelocytic leukemia with TNRC18::RARA fusion","volume":"63","author":"Xu","year":"2024","journal-title":"Mol Carcinog"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828852","article-title":"Clinical response to venetoclax and decitabine in acute promyelocytic leukemia with a novel RARA-THRAP3 fusion: A case report","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2399362","article-title":"Successfully treatment of PLZF-RAR\u03b1 positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review","volume":"29","author":"Zhou","year":"2024","journal-title":"Hematology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2024.100482","article-title":"Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene","volume":"22","author":"Li","year":"2024","journal-title":"Leuk Res Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2430044","article-title":"First case of acute promyelocytic leukemia with TFG-RARA achieved complete remission treated with venetoclax and all-trans retinoic acid","volume":"29","author":"Zhu","year":"2024","journal-title":"Hematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693670","article-title":"Treatment of central nervous system relapse in acute promyelocytic leukemia by venetoclax: A case report","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19763","article-title":"Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia","volume":"205","author":"Yanada","year":"2024","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05270-x","article-title":"Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia","volume":"102","author":"Luo","year":"2023","journal-title":"Ann Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05776-y","article-title":"Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide","volume":"103","author":"Gao","year":"2024","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14413","article-title":"Hydrocortisone improved dexamethasone-induced neuropsychological adverse effects","volume":"63","author":"Oyake","year":"2021","journal-title":"Pediatr Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2024.08.002","article-title":"Cardiotoxicity of anthracyclines","volume":"43","author":"Balough","year":"2025","journal-title":"Cardiol Clin"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:14:04Z","timestamp":1758168844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1671529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1671529"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1671529","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1671529"}}